Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Sarcoma 1Other solid neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma, Alveolar 1Lymphoma 1

Interventions

Cyclophosphamide 55Specimen Handling 50Magnetic Resonance Spectroscopy 49Doxorubicin 44pembrolizumab 43Radiotherapy 42Temozolomide 38Biopsy 34Radiation 29Nivolumab 28fludarabine 23Vincristine 22Irinotecan 21Gemcitabine 21X-Rays 20Ifosfamide 20Surgical Procedures, Operative 19atezolizumab 17cabozantinib 15Ipilimumab 15olaparib 13Sunitinib 13Paclitaxel 13Etoposide 13Blood Specimen Collection 13regorafenib 12fludarabine phosphate 12Phantoms, Imaging 12Imatinib Mesylate 12liposomal doxorubicin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
BAY 1895344 × Sarcoma × 1 year × Clear all
NCT05071209 2026-01-23

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
31 enrolled 14 charts
LymphoidSarcoma

Lymphoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡